Stock 603939 YIFENG PHARMACY CHAIN CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Yifeng Pharmacy Chain Co., Ltd.

Equities

603939

CNE100001TS5

Drug Retailers

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-04-29 pm EDT 		5-day change 1st Jan Change
43.94 CNY +2.16% Intraday chart for Yifeng Pharmacy Chain Co., Ltd. +1.48% +9.74%
Apr. 28 Yifeng Pharmacy Chain Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Mar. 25 Yifeng Pharmacy Chain Lists 1.80 Billion Yuan Worth of Convertible Bonds on Shanghai Bourse MT

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023 2024 2025
Capitalization 1 15,713 27,745 47,897 39,611 46,074 44,405 44,405 -
Enterprise Value (EV) 1 15,713 27,132 46,953 37,992 43,468 38,490 40,993 37,137
P/E ratio 36.5 x 50.8 x 62 x 44.4 x 36.3 x 28.6 x 25.3 x 20.6 x
Yield 0.72% 0.41% 0.33% 0.54% 0.63% 1.25% 1.33% 1.34%
Capitalization / Revenue 2.27 x 2.7 x 3.64 x 2.58 x 2.32 x 1.79 x 1.62 x 1.3 x
EV / Revenue 2.27 x 2.64 x 3.57 x 2.48 x 2.19 x 1.7 x 1.49 x 1.08 x
EV / EBITDA 21.6 x 27 x 34.1 x 23.7 x 19.6 x 15.7 x 10.6 x 8.97 x
EV / FCF 56.4 x 53 x - - - 9.87 x 10.5 x 13.1 x
FCF Yield 1.77% 1.89% - - - 10.1% 9.5% 7.66%
Price to Book 3.87 x 6.15 x 9.13 x 5.29 x 5.38 x 4.13 x 3.97 x 3.4 x
Nbr of stocks (in thousands) 960,102 965,495 966,544 1,006,271 1,010,387 1,010,580 1,010,580 -
Reference price 2 16.37 28.74 49.55 39.36 45.60 43.94 43.94 43.94
Announcement Date 4/9/19 4/8/20 4/27/21 4/28/22 4/27/23 4/28/24 - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023 2024 2025
Net sales 1 6,913 10,276 13,145 15,326 19,886 22,588 27,431 34,270
EBITDA 1 726.2 1,006 1,379 1,600 2,218 2,456 3,885 4,141
EBIT 1 578.3 815.5 1,170 1,339 1,886 2,055 2,587 3,256
Operating Margin 8.37% 7.94% 8.9% 8.74% 9.48% 9.1% 9.43% 9.5%
Earnings before Tax (EBT) 1 581.3 814.3 1,164 1,338 1,877 2,038 2,564 3,228
Net income 1 416.4 543.8 768.3 887.9 1,266 1,412 1,752 2,181
Net margin 6.02% 5.29% 5.84% 5.79% 6.36% 6.25% 6.39% 6.36%
EPS 2 0.4490 0.5659 0.7994 0.8857 1.257 1.400 1.735 2.136
Free Cash Flow 1 278.5 511.4 - - - 3,900 3,895 2,844
FCF margin 4.03% 4.98% - - - 17.26% 14.2% 8.3%
FCF Conversion (EBITDA) 38.35% 50.84% - - - 158.76% 100.26% 68.68%
FCF Conversion (Net income) 66.88% 94.06% - - - 276.18% 222.26% 130.42%
Dividend per Share 2 0.1177 0.1177 0.1648 0.2143 0.2857 0.5000 0.5862 0.5875
Announcement Date 4/9/19 4/8/20 4/27/21 4/28/22 4/27/23 4/28/24 - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 S1 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 4,388 4,148 4,602 4,598 6,539 5,266 5,441 - 5,181 6,700 5,971 6,684 6,605 7,961 8,017 8,535
EBITDA 1 299.4 481.4 - - - - - - - - - 1,140 1,127 1,180 1,241 1,306
EBIT 1 307.2 407.3 443.1 366.9 668.2 501.7 531.1 - 436.1 586 593.5 671.6 595.4 648.1 748.9 817.8
Operating Margin 7% 9.82% 9.63% 7.98% 10.22% 9.53% 9.76% - 8.42% 8.75% 9.94% 10.05% 9.01% 8.14% 9.34% 9.58%
Earnings before Tax (EBT) 1 306.2 407.3 446 366.5 657.8 500.8 530.9 1,032 436.1 569.8 593.2 645.9 633 711.5 763.5 829.9
Net income 1 191.9 272.2 304.2 247.2 442 336.5 368.7 705.2 294 412.8 406.8 447.6 438.6 497.4 529.1 575.1
Net margin 4.37% 6.56% 6.61% 5.38% 6.76% 6.39% 6.78% - 5.67% 6.16% 6.81% 6.7% 6.64% 6.25% 6.6% 6.74%
EPS 2 0.1929 0.2714 0.3000 0.2429 0.4429 0.3357 0.3643 - 0.2900 0.4100 0.4000 0.4365 0.3970 0.4961 0.5018 0.5691
Dividend per Share 2 - - - - - - - - - - - 0.5000 - - - 0.6340
Announcement Date 4/28/22 4/28/22 8/29/22 10/28/22 4/27/23 4/27/23 8/29/23 8/29/23 10/30/23 4/28/24 4/28/24 - - - - -
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023 2024 2025
Net Debt 1 - - - - - - - -
Net Cash position 1 - 613 945 1,619 2,606 1,974 3,412 7,268
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 278 511 - - - 3,900 3,895 2,844
ROE (net income / shareholders' equity) 12.4% 12.7% 15.5% 13% 15.8% 15.4% 16.5% 17.5%
ROA (Net income/ Total Assets) 6.58% 6.38% 6.95% 5.48% - 6.77% 7.5% 7.25%
Assets 1 6,326 8,521 11,062 16,190 - 21,203 23,366 30,078
Book Value Per Share 2 4.230 4.670 5.430 7.430 8.470 9.700 11.10 12.90
Cash Flow per Share 2 0.5300 1.000 1.380 2.140 3.880 4.580 4.130 3.510
Capex 1 232 452 579 821 578 724 1,053 899
Capex / Sales 3.36% 4.4% 4.4% 5.36% 2.91% 3.21% 3.84% 2.62%
Announcement Date 4/9/19 4/8/20 4/27/21 4/28/22 4/27/23 4/28/24 - -
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Yifeng Pharmacy Chain Co., Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
43.94 CNY
Average target price
52.06 CNY
Spread / Average Target
+18.48%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Drug Retailers

1st Jan change Capi.
YIFENG PHARMACY CHAIN CO., LTD. Stock Yifeng Pharmacy Chain Co., Ltd.
+9.74% 6.14B
WALGREENS BOOTS ALLIANCE, INC. Stock Walgreens Boots Alliance, Inc.
-31.79% 15.36B
JD HEALTH INTERNATIONAL INC. Stock JD Health International Inc.
-21.99% 12.45B
ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED Stock Alibaba Health Information Technology Limited
-22.64% 6.75B
MATSUKIYOCOCOKARA & CO. Stock MatsukiyoCocokara & Co.
-10.91% 6.07B
NAHDI MEDICAL COMPANY Stock Nahdi Medical Company
+0.58% 4.78B
CORPORATIVO FRAGUA, S.A.B. DE C.V. Stock Corporativo Fragua, S.A.B. de C.V.
+59.24% 4.53B
CLICKS GROUP LIMITED Stock Clicks Group Limited
-9.00% 3.81B
DASHENLIN PHARMACEUTICAL GROUP CO., LTD. Stock DaShenLin Pharmaceutical Group Co., Ltd.
-12.53% 3.43B
WELCIA HOLDINGS CO., LTD. Stock Welcia Holdings Co., Ltd.
-7.34% 3.09B
Other Drug Retailers
  1. Stock Market
  2. Equities
  3. 603939 Stock
  4. Financials Yifeng Pharmacy Chain Co., Ltd.